Related Experiment Video

Updated: Apr 26, 2026

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
09:21

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

119

Resistance to antiangiogenic therapies

Marco Bartolotti1, Enrico Franceschi, Rosalba Poggi

  • 1Department of Medical Oncology, Azienda Unità Sanitaria Locale, Bologna, Italy.

Future Oncology (London, England)
|July 24, 2014
PubMed

Insights

Angiogenesis is crucial for tumor growth and a target for cancer therapies. However, tumors often develop resistance to antiangiogenic drugs, necessitating research into overcoming this resistance.

Area of Science:

  • Oncology and Cancer Biology
  • Tumor Microenvironment Research
  • Pharmacology and Drug Development

Background:

  • Angiogenesis, the formation of new blood vessels, is essential for tumor growth and metastasis.
  • Antiangiogenic agents targeting vascular endothelial growth factor (VEGF) and its receptor are standard cancer treatments.
  • Tumor resistance to antiangiogenic therapies is a significant clinical challenge, limiting treatment efficacy.

Purpose of the Study:

  • To investigate mechanisms of resistance to antiangiogenic drugs in preclinical cancer models.
  • To identify therapeutic strategies for restoring sensitivity to antiangiogenic agents.
  • To evaluate potential biomarkers for predicting patient response or resistance to antiangiogenic therapy.

Main Methods:

  • Preclinical studies utilizing various tumor models.
  • Investigating molecular pathways and signaling molecules involved in antiangiogenic drug resistance.
  • Testing novel agents designed to overcome resistance mechanisms.

Main Results:

  • Several mechanisms contributing to resistance against antiangiogenic drugs have been identified.
  • Certain agents have shown promise in preclinical models by restoring sensitivity to antiangiogenic therapies.
  • The evaluation of biomarkers for treatment response prediction is ongoing.

Conclusions:

  • Understanding resistance mechanisms is critical for improving antiangiogenic cancer therapy.
  • Targeting resistance pathways offers a potential strategy to enhance the efficacy of antiangiogenic drugs.
  • Further research is needed to translate these findings into clinical practice and develop predictive biomarkers.
Keywords:
angiogenesisantiangiogenicbevacizumabresistance

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

6.5K
Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization05:14

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Published on: August 11, 2023

1.7K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.1K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.9K
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
6.3K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.1K